Arkansas' Ezra Innovations is hoping its proprietary extended-release delivery tech can help it close a $6.5 million funding round. Using a novel drug design licensed from the University of Arkansas, the company wants to apply its method to generics. It figures its technology will allow for fewer doses and improved patient compliance, MedCity News reports. While it's unknown what meds Ezra is targeting, there are a number of blockbusters with soon-to-expire patents--including Cymbalta and Singulair--and the company's platform could help it get a leg up in the coming generic onslaught. Ezra has nailed down $4.2 million from 33 investors since April 2011. More